AU2018311804B2 - Anti-CD137 antibodies - Google Patents

Anti-CD137 antibodies Download PDF

Info

Publication number
AU2018311804B2
AU2018311804B2 AU2018311804A AU2018311804A AU2018311804B2 AU 2018311804 B2 AU2018311804 B2 AU 2018311804B2 AU 2018311804 A AU2018311804 A AU 2018311804A AU 2018311804 A AU2018311804 A AU 2018311804A AU 2018311804 B2 AU2018311804 B2 AU 2018311804B2
Authority
AU
Australia
Prior art keywords
seq
antibody
cancer
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018311804A
Other languages
English (en)
Other versions
AU2018311804A1 (en
Inventor
Christopher Carl Frye
Michael Dewain Kalos
Helen KOTANIDES
Stephanie Lynn SANDEFUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2018311804A1 publication Critical patent/AU2018311804A1/en
Application granted granted Critical
Publication of AU2018311804B2 publication Critical patent/AU2018311804B2/en
Priority to AU2021277707A priority Critical patent/AU2021277707A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L7/00—Arrangements for synchronising receiver with transmitter
    • H04L7/04—Speed or phase control by synchronisation signals
    • H04L7/10—Arrangements for initial synchronisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/25—Arrangements specific to fibre transmission
    • H04B10/2575—Radio-over-fibre, e.g. radio frequency signal modulated onto an optical carrier
    • H04B10/25752—Optical arrangements for wireless networks
    • H04B10/25753—Distribution optical network, e.g. between a base station and a plurality of remote units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018311804A 2017-08-01 2018-07-25 Anti-CD137 antibodies Active AU2018311804B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021277707A AU2021277707A1 (en) 2017-08-01 2021-12-02 Anti-cd137 antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539687P 2017-08-01 2017-08-01
US62/539,687 2017-08-01
PCT/US2018/043632 WO2019027754A1 (en) 2017-08-01 2018-07-25 ANTI-CD137 ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277707A Division AU2021277707A1 (en) 2017-08-01 2021-12-02 Anti-cd137 antibodies

Publications (2)

Publication Number Publication Date
AU2018311804A1 AU2018311804A1 (en) 2020-02-13
AU2018311804B2 true AU2018311804B2 (en) 2021-09-02

Family

ID=63165504

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018311804A Active AU2018311804B2 (en) 2017-08-01 2018-07-25 Anti-CD137 antibodies
AU2021277707A Abandoned AU2021277707A1 (en) 2017-08-01 2021-12-02 Anti-cd137 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021277707A Abandoned AU2021277707A1 (en) 2017-08-01 2021-12-02 Anti-cd137 antibodies

Country Status (25)

Country Link
US (3) US10906983B2 (https=)
EP (2) EP4070811A1 (https=)
JP (2) JP6743320B1 (https=)
KR (2) KR102344620B1 (https=)
CN (1) CN111182919B (https=)
AU (2) AU2018311804B2 (https=)
BR (1) BR112020001441A2 (https=)
CA (2) CA3071383C (https=)
CL (1) CL2020000233A1 (https=)
CO (1) CO2020001050A2 (https=)
CR (1) CR20200042A (https=)
DO (1) DOP2020000020A (https=)
EA (1) EA202090204A1 (https=)
EC (1) ECSP20007663A (https=)
ES (1) ES2912651T3 (https=)
IL (1) IL272349B2 (https=)
JO (1) JOP20200016B1 (https=)
MA (1) MA49749A (https=)
MX (1) MX2020001351A (https=)
PE (1) PE20200839A1 (https=)
PH (1) PH12020500225A1 (https=)
SA (1) SA520411186B1 (https=)
SG (1) SG11202000747VA (https=)
UA (1) UA128388C2 (https=)
WO (1) WO2019027754A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CA3071383C (en) 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20240017090A (ko) * 2018-03-23 2024-02-06 일라이 릴리 앤드 캄파니 항-pd-1 항체와의 조합을 위한 항-cd137 항체
CA3094763C (en) * 2018-03-23 2024-01-02 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3285695A1 (en) 2019-06-26 2026-03-02 Ap Biosciences, Inc. Antibodies for t-cell activation
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
JP2024501127A (ja) 2020-11-25 2024-01-11 上海君賽生物科技有限公司 腫瘍浸潤リンパ球培地及びその使用
CN120769904A (zh) 2023-02-27 2025-10-10 上海君赛生物科技有限公司 表达膜结合细胞因子的肿瘤浸润淋巴细胞
KR20250104669A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 선택 가이드 정보 제공 방법 및 그 장치
KR20250104655A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치
KR20250132789A (ko) 2024-02-29 2025-09-05 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US8337850B2 (en) * 2010-09-09 2012-12-25 Pfizer Inc. 4-1BB binding molecules
US20160244528A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
RU2192281C2 (ru) 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
CA3071383C (en) * 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US8337850B2 (en) * 2010-09-09 2012-12-25 Pfizer Inc. 4-1BB binding molecules
US20160244528A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIMOTHY S. FISHER ET AL, CANCER IMMUNOLOGY, IMMUNOTHERAPY, Berlin/Heidelberg, (2012-03-11), vol. 61, no. 10, doi:10.1007/s00262-012-1237-1, ISSN 0340-7004, pages 1721 - 1733 *

Also Published As

Publication number Publication date
CR20200042A (es) 2020-03-03
ECSP20007663A (es) 2020-06-30
EA202090204A1 (ru) 2020-05-22
JP2020527356A (ja) 2020-09-10
CA3146758A1 (en) 2019-02-07
EP4070811A1 (en) 2022-10-12
SA520411186B1 (ar) 2025-06-29
US12453771B2 (en) 2025-10-28
KR102344620B1 (ko) 2022-01-03
IL272349B1 (en) 2024-05-01
IL272349B2 (en) 2024-09-01
BR112020001441A2 (pt) 2020-08-04
EP3661544A1 (en) 2020-06-10
AU2021277707A1 (en) 2021-12-23
US20200377607A1 (en) 2020-12-03
US20260109775A1 (en) 2026-04-23
JOP20200016B1 (ar) 2022-10-30
IL272349A (en) 2020-03-31
MA49749A (fr) 2021-03-24
CL2020000233A1 (es) 2020-07-31
KR20200023439A (ko) 2020-03-04
JP6743320B1 (ja) 2020-08-19
CA3071383A1 (en) 2019-02-07
CN111182919B (zh) 2023-07-07
JOP20200016A1 (ar) 2020-01-28
WO2019027754A1 (en) 2019-02-07
US10906983B2 (en) 2021-02-02
ES2912651T3 (es) 2022-05-26
UA128388C2 (uk) 2024-07-03
NZ761548A (en) 2024-07-05
PE20200839A1 (es) 2020-08-13
PH12020500225A1 (en) 2020-11-09
DOP2020000020A (es) 2020-02-28
EP3661544B1 (en) 2022-04-13
JP7257364B2 (ja) 2023-04-13
CN111182919A (zh) 2020-05-19
CA3071383C (en) 2022-04-12
JP2020182492A (ja) 2020-11-12
CO2020001050A2 (es) 2020-02-18
SG11202000747VA (en) 2020-02-27
US20230279134A1 (en) 2023-09-07
KR20210158420A (ko) 2021-12-30
AU2018311804A1 (en) 2020-02-13
MX2020001351A (es) 2020-03-09

Similar Documents

Publication Publication Date Title
AU2018311804B2 (en) Anti-CD137 antibodies
KR101601387B1 (ko) c-KIT 항체 및 이의 용도
KR20250038810A (ko) 항-pd-1 항체와의 조합을 위한 항-cd137 항체
AU2019239194B2 (en) Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
JP2020524988A (ja) 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用
US11512134B2 (en) Anti-CD137 antibodies
HK40081907A (en) Anti-cd137 antibodies
HK40019208B (en) Anti-cd137 antibodies
HK40045294B (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
HK40045294A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
EA043217B1 (ru) Анти-cd137 антитела

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)